125I-Iododeoxyuridine for the Treatment of a Brain Tumor Model: Selection of Conditions for Optimal Effectiveness

Abstract

Abstract:The intent of this study was to optimise conditions for the use of 125 IUdR in the treatment of cancer. The radiopharmaceutical plus a biomodulator, methotrexate (MTX) was delivered by intra-tumoral injection of a thermosensitive hydrogel forming a slow release depot of 125 IUdR and MTX in the tumor.Methods: The C6 rat glioblastoma was implanted intra-cranially. A chitosan polymer was used to formulate a biodegradable and biocompatible implant for controlled intra-tumoral delivery of 125 IUdR plus MTX.Results: Intratumoral implant of hydrogel loaded with 7.0 -7.4 MBq of 125 IUdR resulted in survival of 20% of treated animals to 180 days after tumor implant. Simultaneous delivery of MTX increased the number of rats that were effectively cured, to 40%. Conclusion:Using an injectable thermolabile hydrogel as vehicle for 125 IUdR delivery a higher level of tumor control was achieved in a rat glioma model than had been previously reported.

Molecular and cellular effects of Auger emitters: 2008–2011

“…Th e methotrexate combination lessened side-eff ects, inhibited tumor cell growth and is known to augment the therapeutic potential of 125 IdU in the intrathecal TE0671 human rhabdomyosarcoma (Kassis et al 2004). Recent studies by Lehnert et al (2011) use a hydrogel implanted with 125 IUdR and methotrexate in a C6 rat glioblastoma model.…”